70 related articles for article (PubMed ID: 23330264)
1. [Treatment of hepatitis C virus--2012: a real breakthrough].
Zuckerman E
Harefuah; 2012 Dec; 151(12):699-704, 719. PubMed ID: 23330264
[TBL] [Abstract][Full Text] [Related]
2. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
[TBL] [Abstract][Full Text] [Related]
3. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Welsch C; Jesudian A; Zeuzem S; Jacobson I
Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.
Chevaliez S
Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S46-51. PubMed ID: 22248694
[TBL] [Abstract][Full Text] [Related]
5. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
6. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
7. [Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance].
Chueca Porcuna N; Alvarez Estévez M; Parra Ruiz J; Hernández Quero J; García García F
Enferm Infecc Microbiol Clin; 2013 Feb; 31 Suppl 1():40-7. PubMed ID: 23453230
[TBL] [Abstract][Full Text] [Related]
8. [Chronic hepatitis C infection--eradication of the virus].
Ben Ari Z
Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies for hepatitis C virus.
Birerdinc A; Younossi ZM
Expert Opin Emerg Drugs; 2010 Dec; 15(4):535-44. PubMed ID: 20629602
[TBL] [Abstract][Full Text] [Related]
11. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
12. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
Shah N; Pierce T; Kowdley KV
Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
[TBL] [Abstract][Full Text] [Related]
13. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.
Nguyen NH; Nguyen MH
Gastroenterol Clin North Am; 2015 Dec; 44(4):871-81. PubMed ID: 26600225
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).
Sheridan DA; Neely RD; Bassendine MF
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):10-6. PubMed ID: 22959093
[TBL] [Abstract][Full Text] [Related]
15. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.
Zeisel MB; Lupberger J; Fofana I; Baumert TF
J Hepatol; 2013 Feb; 58(2):375-84. PubMed ID: 23041307
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients.
Kanda T; Yokosuka O; Omata M
Chin Med J (Engl); 2013 Dec; 126(23):4568-74. PubMed ID: 24286427
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
[TBL] [Abstract][Full Text] [Related]
18. HCV drug resistance and DAA agents.
Szymanek A; Krzysztof S
Przegl Epidemiol; 2013; 67(3):403-6, 513-5. PubMed ID: 24340550
[TBL] [Abstract][Full Text] [Related]
19. The current treatment of Hepatitis C.
Arleo A; Mangia A
Minerva Gastroenterol Dietol; 2016 Jun; 62(2):167-82. PubMed ID: 26799657
[TBL] [Abstract][Full Text] [Related]
20. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
Girardin F; Goossens N; Vernaz N; Negro F
Rev Med Suisse; 2015 Sep; 11(484):1610-2, 1614-6. PubMed ID: 26502622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
